BioCardia Statistics
Total Valuation
BioCardia has a market cap or net worth of $10.87 million. The enterprise value is $10.77 million.
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025, after market close.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioCardia has 5.18 million shares outstanding. The number of shares has increased by 133.10% in one year.
| Current Share Class | 5.18M |
| Shares Outstanding | 5.18M |
| Shares Change (YoY) | +133.10% |
| Shares Change (QoQ) | +1.05% |
| Owned by Insiders (%) | 23.07% |
| Owned by Institutions (%) | 4.75% |
| Float | 3.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3,624.52 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3,591.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.36
| Current Ratio | 0.36 |
| Quick Ratio | 0.29 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -218.06% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 791.39% |
| Revenue Per Employee | $150 |
| Profits Per Employee | -$419,550 |
| Employee Count | 20 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.59% in the last 52 weeks. The beta is 0.84, so BioCardia's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | -27.59% |
| 50-Day Moving Average | 2.27 |
| 200-Day Moving Average | 2.36 |
| Relative Strength Index (RSI) | 47.50 |
| Average Volume (20 Days) | 51,292 |
Short Selling Information
The latest short interest is 13,462, so 0.26% of the outstanding shares have been sold short.
| Short Interest | 13,462 |
| Short Previous Month | 23,060 |
| Short % of Shares Out | 0.26% |
| Short % of Float | 0.35% |
| Short Ratio (days to cover) | 0.23 |
Income Statement
In the last 12 months, BioCardia had revenue of $3,000 and -$8.39 million in losses. Loss per share was -$2.41.
| Revenue | 3,000 |
| Gross Profit | -4.67M |
| Operating Income | -8.45M |
| Pretax Income | n/a |
| Net Income | -8.39M |
| EBITDA | -8.39M |
| EBIT | -8.45M |
| Loss Per Share | -$2.41 |
Full Income StatementBalance Sheet
The company has $949,000 in cash and $850,000 in debt, giving a net cash position of $99,000 or $0.02 per share.
| Cash & Cash Equivalents | 949,000 |
| Total Debt | 850,000 |
| Net Cash | 99,000 |
| Net Cash Per Share | $0.02 |
| Equity (Book Value) | -1.52M |
| Book Value Per Share | -0.32 |
| Working Capital | -2.06M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$8.11 million and capital expenditures -$6,000, giving a free cash flow of -$8.12 million.
| Operating Cash Flow | -8.11M |
| Capital Expenditures | -6,000 |
| Free Cash Flow | -8.12M |
| FCF Per Share | -$1.57 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -281,733.33% |
| Pretax Margin | -279,700.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioCardia does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -133.10% |
| Shareholder Yield | -133.10% |
| Earnings Yield | -77.17% |
| FCF Yield | -74.68% |
Analyst Forecast
The average price target for BioCardia is $25.00, which is 1,090.48% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $25.00 |
| Price Target Difference | 1,090.48% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 30, 2024. It was a reverse split with a ratio of 0.0666667:1.
| Last Split Date | May 30, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0666667:1 |
Scores
BioCardia has an Altman Z-Score of -117.79 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -117.79 |
| Piotroski F-Score | 2 |